Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells

Cell Stress and Chaperones

Volumn 20, Issue 1, 2015, Pages 149-157

  Park, Sangkyu ^a   Park, Jeong A ^a   Kim, Young Eun ^a   Song, Sukgil ^a   Kwon, Hyung Joo ^b   Lee, Younghee ^a  

^a Chungbuk National University   (South Korea)

^b Hallym University   (South Korea)

Author keywords

Cleavage; HSP90; K562; ROS; Suberoylanilide hydroxamic acid

Indexed keywords

ACETYLCYSTEINE; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; CASPASE; CASPASE 10; CASPASE INHIBITOR; FAS ANTIGEN; FAS PROTEIN, HUMAN; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE INHIBITOR; HYDROGEN PEROXIDE; HYDROXAMIC ACID; PEPTIDE CHLOROMETHYL KETONE; REACTIVE OXYGEN METABOLITE; VORINOSTAT;

CHEMISTRY; DRUG EFFECTS; HUMAN; IMMUNOLOGY; K562 CELL LINE; LEUKEMIA; METABOLISM; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION;

ACETYLCYSTEINE; AMINO ACID CHLOROMETHYL KETONES; ANTIGENS, CD95; CASPASE 10; CASPASE INHIBITORS; CASPASES; HISTONE DEACETYLASE INHIBITORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDROGEN PEROXIDE; HYDROXAMIC ACIDS; K562 CELLS; LEUKEMIA; PROTEOLYSIS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84914665697     PISSN: 13558145     EISSN: 14661268     Source Type: Journal    
DOI: 10.1007/s12192-014-0533-4     Document Type: Article

References (44)

1. Bali P, Pranpat M, Bradner J, Balasis M, Fiskus W, Guo F, Rocha K, Kumaraswamy S, Boyapalle S, Atadja P, Seto E, Bhalla K (2005) Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 280(29):26729–26734
2. Beck R, Verrax J, Gonze T, Zappone M, Pedrosa RC, Taper H, Feron O, Calderon PB (2009) Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death. Biochem Pharmacol 77(3):375–383
3. Beck R, Dejeans N, Glorieux C, Creton M, Delaive E, Dieu M, Raes M, Leveque P, Gallez B, Depuydt M, Collet JF, Calderon PB, Verrax J (2012) Hsp90 is cleaved by reactive oxygen species at a highly conserved N-terminal amino acid motif. PLoS One 7(7):e40795
4. Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769–784
5. Boltze C, Lehnert H, Schneider-Stock R, Peters B, Hoang-Vu C, Roessner A (2003) HSP90 is a key for telomerase activation and malignant transition in pheochromocytoma. Endocrine 22(3):193–201
6. Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 99(18):11700–11705
7. Cai J, Jones DP (1998) Superoxide in apoptosis. Mitochondrial generation triggered by cytochrome c loss. J Biol Chem 273(19):11401–11404
8. Chen H, Xia Y, Fang D, Hawke D, Lu Z (2009) Caspase-10-mediated heat shock protein 90 beta cleavage promotes UVB irradiation-induced cell apoptosis. Mol Cell Biol 29(13):3657–3664
9. Cheong JW, Chong SY, Kim JY, Eom JI, Jeung HK, Maeng HY, Lee ST, Min YH (2003) Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells. Clin Cancer Res 9(13):5018–5027
10. Dickson MA, Okuno SH, Keohan ML, Maki RG, D’Adamo DR, Akhurst TJ, Antonescu CR, Schwartz GK (2013) Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann Oncol 24(1):252–257
11. Dokmanovic M, Clarke C, Marks PA (2007) Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 5(10):981–989
12. Dypbukt JM, Ankarcrona M, Burkitt M, Sjoholm A, Strom K, Orrenius S, Nicotera P (1994) Different prooxidant levels stimulate growth, trigger apoptosis, or produce necrosis of insulin-secreting RINm5F cells. The role of intracellular polyamines. J Biol Chem 269(48):30553–30560
13. Ferrarini M, Heltai S, Zocchi MR, Rugarli C (1992) Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 51(4):613–619
14. Gillenwater AM, Zhong M, Lotan R (2007) Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells. Mol Cancer Ther 6(11):2967–2975
15. Hole PS, Darley RL, Tonks A (2011) Do reactive oxygen species play a role in myeloid leukemias? Blood 117(22):5816–5826
16. Junn E, Han SH, Im JY, Yang Y, Cho EW, Um HD, Kim DK, Lee KW, Han PL, Rhee SG, Choi I (2000) Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 164(12):6287–6295
17. Kamata H, Hirata H (1999) Redox regulation of cellular signalling. Cell Signal 11(1):1–14
18. Kang J, Chen J, Zhang D, Da W, Ou Y (2004) Synergistic killing of human leukemia cells by antioxidants and trichostatin A. Cancer Chemother Pharmacol 54(6):537–545
19. Kelly WK, O’Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, Richardson S, Chu E, Olgac S, Marks PA, Scher H, Richon VM (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23(17):3923–3931
20. Kim BM, Chung HW (2007) Hypoxia/reoxygenation induces apoptosis through a ROS-mediated caspase-8/Bid/Bax pathway in human lymphocytes. Biochem Biophys Res Commun 363(3):745–750
21. Kim YJ, Kim D, Lee Y, Choi SY, Park J, Lee SY, Park JW, Kwon HJ (2009) Effects of nanoparticulate saponin-platinum conjugates on 2,4-dinitrofluorobenzene-induced macrophage inflammatory protein-2 gene expression via reactive oxygen species production in RAW 264.7 cells. BMB Rep 42(5):304–309
22. Kornberg RD (1999) Eukaryotic transcriptional control. Trends Cell Biol 9(12):M46–49
23. Kwon SH, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee YW, Lee HW, Han JW (2002) Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J Biol Chem 277(3):2073–2080
24. Liu SH, Lin CH, Liang FP, Chen PF, Kuo CD, Alam MM, Maiti B, Hung SK, Chi CW, Sun CM, Fu SL (2014) Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy. Biochem Pharmacol 87(2):229–242
25. Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92(15):1210–1216
26. Miyata Y, Nakamoto H, Neckers L (2013) The therapeutic target Hsp90 and cancer hallmarks. Curr Pharm Des 19(3):347–365
27. Modi S, Stopeck A, Linden H, Solit D, Chandarlapaty S, Rosen N, D’Andrea G, Dickler M, Moynahan ME, Sugarman S, Ma W, Patil S, Norton L, Hannah AL, Hudis C (2011) HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res 17(15):5132–5139
28. Neckers L, Workman P (2012) Hsp90 molecular chaperon inhibitors: are we there yet? Clin Cancer Res 18(1):64–76
29. Neckers L, Mimnaugh E, Schulte TW (1999) Hsp90 as an anti-cancer target. Drug Resist Updat 2(3):165–172
30. Nishioka C, Ikezoe T, Yang J, Takeuchi S, Koeffler HP, Yokoyama A (2008) MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells. Leuk Res 32(9):1382–1392
31. O’Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, MacGregor-Cortelli B, Curly T, Moskowitz C, Portlock C, Horwitz S, Zelenetz AD, Frankel S, Richon V, Marks P, Kelly WK (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 24(1):166–173
32. Prodromou C, Roe SM, O’Brien R, Ladbury JE, Piper PW, Pearl LH (1997) Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 90(1):65–75
33. Prodromou C, Panaretou B, Chohan S, Siligardi G, O’Brien R, Ladbury JE, Roe SM, Piper PW, Pearl LH (2000) The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. EMBO J 19(16):4383–4392
34. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 97(18):10014–10019
35. Richter K, Buchner J (2001) Hsp90: chaperoning signal transduction. J Cell Physiol 188(3):281–290
36. Röhl A, Rohrberg J, Buchner J (2013) The chaperone Hsp90: changing partners for demanding clients. Trends Biochem Sci 38(5):253–262
37. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 98(19):10833–10838
38. Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsumi S, Beebe K, Cotter RJ, Felts S, Toft D, Karnitz L, Rosen N, Neckers L (2007) An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell 25(1):151–159
39. Shao Y, Gao Z, Marks PA, Jiang X (2004) Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 101(52):18030–18035
40. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P (2008) Redox regulation of cell survival. Antioxid Redox Signal 10(8):1343–1374
41. Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ (2001) Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci U S A 98(24):13884–13888
42. Wang ZB, Liu YQ, Cui YF (2005) Pathways to caspase activation. Cell Biol Int 29(7):489–496
43. Welch WJ (1993) How cells respond to stress. Sci Am 268(5):56–64
44. Zuehlke A, Johnson JL (2010) Hsp90 and co-chaperones twist the functions of diverse client proteins. Biopolymers 93(3):211–217